Image source: © 2025 Krish Capital Pty. Ltd.

Highlights

  • TLX’s FY24 operating profit surged 423% YoY, while adjusted EBITDA rose 70% YoY.
  • TLX plans three new diagnostic product launches in 2025, pending approvals in the U.S. and Europe.
  • TLX projects FY25 revenue of AUD 1.18–1.23 billion and plans to increase R&D spending by 20–25%.

Telix Pharmaceuticals Limited (ASX:TLX) is a Melbourne-based biopharmaceutical company, engaged in the development and commercialisation of radiopharmaceuticals and related devices for oncology and rare diseases. Its lead imaging product is Illuccix®, which has received approvals from Health Canada, the TGA and the FDA.

In the financial year 2024 (FY24), the company’s revenue rose by 56% YoY to AUD 783.2 million, fuelled by higher Illuccix® sales, new product launches, and expanded global reach. The operating profit for the period surged by 423% YoY, while adjusted EBITDA increased by 70% YoY. The operating cash flow grew by 80% YoY to AUD 43.0 million in FY24, up from AUD 23.9 million in FY23.

During the first quarter of the financial year 2025 (Q1 FY25), the company’s revenue increased by 62% YoY to USD 186 million, primarily driven by higher sales of Illuccix® and the recent acquisition of RSL radiopharmacies.

Business Update

The company’s PSMA PET imaging agent, Gozellix®, has received a permanent HCPCS code from CMS, effective October 2025. This milestone enables reimbursement, boosts clinical adoption and commercial growth, and expands access to precision imaging for prostate cancer patients in the U.S.

Company Outlook

TLX projects FY25 revenue of AUD 1.18–1.23 billion, supported by sustained Illuccix® sales and acquisitions like RLS, while planning a 20–25% increase in R&D spending to advance late-stage oncology and rare disease clinical programs. Additionally, the company aims to launch three new diagnostic products in 2025, targeting revenue growth through expanded market presence in the U.S. and Europe, pending regulatory approvals.

TLX plans to enhance its global supply chain and manufacturing, including GMP production expansion, to boost international distribution and access. The company plans to advance key therapeutic programs, including the ProstACT GLOBAL Phase 3 trial and alpha therapy candidates, through pivotal clinical development stages.

Share performance of TLX

TLX shares closed 0.88% higher at AUD 24.030 per share on 16 July 2025. Despite this intraday gain, the stock has declined 5.36% over the past week, 6.13% in the last month, and 7.11% in the past three months. The share surged 13.19% over nine months and 20.57% over the past year.

The 52-week high for TLX is AUD 31.970, recorded on 26 February 2025, while the 52-week low is AUD 17.030, set on 5 September 2024.

Support and Resistance Summary

Note 1: Past performance is neither an Indicator nor a guarantee of future performance.

Note 2: The reference date for all price data, and currency, is 16 July 2025. The reference data in this report has been partly sourced from EODHD/Others.

Technical Indicators Defined:

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.

Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.